<DOC>
	<DOCNO>NCT02456012</DOCNO>
	<brief_summary>The purpose study determine whether long-term prophylactic use esomeprazole 20 mg twice daily daily prevention effectiveness reduce recurrence peptic ulcer bleed ulcer heal 16-week oral esomeprazole therapy high-risk patient whose Rockall score ≥ 6 .</brief_summary>
	<brief_title>Long-term Oral Esomeprazole Prevention Peptic Ulcer Rebleeding High-risk Patients</brief_title>
	<detailed_description>This study conduct inpatient ward National Cheng Kung University Hospital , tertiary health care center Tainan , Taiwan . All participant give write informed consent enrollment . Each enrol patient receives 80 mg load dose intravenous esomeprazole ( Nexium® , AstraZeneca AB , Södertälje , Sweden ) immediately achieve haemostasis gastroscopy . Patients receive 3-day continuous high-dose ( 8 mg/h ) esomeprazole infusion receive 40 mg oral esomeprazole twice daily 11 day daily follow 98 day . The total duration intravenous oral esomeprazole 16 week . After gastroscopy confirm enrollment eligibility ulcer heal , patient assess use Rockall risk score system primary endoscopy . Patients Rockall score ≥ 6 randomize double-dose ( D ) group single-dose ( S ) group follow simple randomization procedure 1:1 allocation ratio accord result investigator draw envelope large box seal envelope contain write code designate D group S group . Patients D group S group receive 20 mg oral esomeprazole twice daily daily 36 week , respectively . The cohort control group include patient previous study peptic ulcer bleed Rockall score ≥ 6 receive esomeprazole proton pump inhibitor 16-week proton pump inhibitor treatment . One investigator generate random allocation sequence enroll participant different investigator assigns participant intervention . The endoscopists staff check hemoglobin level , hemodynamic status , melena , hematochezia aspirate nasogastric tube blind study group allocation . All enrol patient include intention-to-treat ( ITT ) analysis , patient lose follow-up , discontinue intervention adverse event , protocol violation die exclude per-protocol ( PP ) analysis primary endpoint . The range co-morbidities evaluate Rockall score include disseminate malignant disease , liver disease ( liver cirrhosis , Child-Pugh A , B , C ) , renal disease ( end-stage renal disease , chronic kidney disease acute kidney injury estimate glomerular filtration rate &lt; 30 ml/min [ score 3 co-morbidity ] , 30 ml/min 60 ml/min [ score 2 co-morbidity ] ) , heart disease ( congestive heart failure , New York Heart Association Function I IV coronary artery disease ) . Other serious co-morbidities include lung disease ( chronic obstructive pulmonary disease , pulmonary tuberculosis , pneumonia empyema ) , rheumatoid arthritis , sepsis , new onset cerebrovascular accident recent history major surgery ( thorax , abdomen , central nervous system , long bone spinal bone ) require general anesthesia within 14 day bleed . The estimated rebleeding rate within 12 month cohort control group 13.4 % base previous study . We want able detect difference cohort control group D group , rebleeding rate propose 2.5 % , equal patient H. pylorus ulcer eradication . With two-side α value 0.05 power 80 % ( β=0.20 ) , total number patient require group 96 . We use nominal 0.05 rate p value . Data related baseline characteristic end point evaluate use Student test , Pearson 's χ2 test Fisher 's exact test Mann-Whitney U test . In survival analysis , log-rank test use compare Kaplan-Meier curve among three study group . All test two-tailed p value less 0.05 indicate significant difference .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Eligible participant include patient ≥20 year undergone gastroscopy melena , haematochezia , haematemesis due bleed peptic ulcer major stigma recent hemorrhage . The major stigma recent haemorrhage classify Forrest class Ia , Ib , IIa , IIb . All stigmata give one combination endoscopic therapy , include local injection dilute epinephrine 1:10000 , bipolar heat probe , argon plasma coagulation , band ligation , hemoclip therapy . Patients undergo followup endoscopy 12 16 week later confirm ulcer heal less 0.5 cm ; otherwise , patient enrol . Patients exclude tumor bleed ulcer bleed due presence Dieulafoy lesion mechanical factor ( e.g , gastrostomy tube induction ) , comorbid reflux esophagitis grade C D , Barrett 's esophagus , marginal ulcer bleeding , hypersensitivity esomeprazole component formulation , previously participate study . Because concern patient safety certain drugdrug interaction , patient receive antiplatelet therapy , e.g. , aspirin , clopidogrel , others prophylaxis establish cardiovascular cerebrovascular disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>peptic ulcer hemorrhage</keyword>
	<keyword>comorbidity</keyword>
	<keyword>clinical trial</keyword>
</DOC>